Form 4: KALA Bio Executive Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Romulus K. Brazzell, Head of Research and Development and Chief Medical Officer at KALA Bio, Inc., sold 5,489 shares of common stock on June 26, 2024, to cover tax withholding obligations related to vested restricted stock units.
Summary
- Romulus K. Brazzell, an executive at KALA Bio, Inc., sold 5,489 shares of common stock on June 26, 2024.
- The sale was executed at a weighted average price of $4.75 per share, with individual transactions ranging from $4.50 to $5.09.
- The transaction was made pursuant to a pre-arranged 10b5-1 trading plan adopted on November 9, 2020.
- The purpose of the sale was to cover tax withholding obligations associated with the vesting and settlement of restricted stock units (RSUs) granted on June 22, 2023.
- Following the reported transaction, Brazzell beneficially owns 83,982 shares of KALA Bio, Inc., which includes 59,293 unvested RSUs.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing related to an executive stock sale. The sale was pre-planned and intended to cover tax obligations, so it doesn't necessarily indicate a positive or negative outlook for the company.
Industry Context
Sales of shares by company executives are a normal part of executive compensation and financial planning. The use of a 10b5-1 trading plan is a common practice to avoid accusations of insider trading, as the plan is established in advance.
Comparison to Industry Standards
- Executive stock sales are a common practice across the biotechnology industry.
- Companies like Amgen, Gilead Sciences, and Biogen also see regular Form 4 filings related to executive stock transactions.
- The use of 10b5-1 trading plans is a standard method for executives to manage their stock holdings while complying with insider trading regulations.
Stakeholder Impact
- The stock sale may have a minor impact on shareholders due to the small volume of shares sold.
- The transaction does not directly affect employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| November 9, 2020 | Date the Reporting Person adopted the 10b5-1 trading plan |
| June 22, 2023 | Date of grant for the restricted stock units (RSUs) |
| June 26, 2024 | Date of the stock sale transaction |
| June 27, 2024 | Date of signature for the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.